Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia

Br J Haematol. 2017 Feb;176(3):498-501. doi: 10.1111/bjh.13971. Epub 2016 Feb 23.

Authors

Affiliations

¹ Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
² Division of Haematology, Centre of Haematology and Haemotherapy of Ceara, Fortaleza, Brazil.
³ Department of Internal Medicine, Cancer Hospital of Pernambuco, Recife, Brazil.
⁴ Department of Internal Medicine, Haematology and Haemotherapy Foundation of Pernambuco, Recife, Brazil.

PMID: 26914377
DOI: 10.1111/bjh.13971

No abstract available

Keywords: Acute myeloid leukaemia; CD56 expression; developing countries; prognostic factors; treatment outcome.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
CD56 Antigen / biosynthesis*
Disease-Free Survival
Female
Humans
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / mortality
Male
Middle Aged
Prognosis
Survival Analysis
Young Adult

Substances

CD56 Antigen